Annual report [Section 13 and 15(d), not S-K Item 405]

Stockholders' Equity (Registration Statements, At-the-Market Offering and Stock Issuances to Fortress) (Details)

v3.25.1
Stockholders' Equity (Registration Statements, At-the-Market Offering and Stock Issuances to Fortress) (Details)
 1 Months Ended 12 Months Ended
Jun. 19, 2024
$ / shares
shares
Jan. 01, 2024
shares
May 24, 2021
USD ($)
shares
Oct. 31, 2024
USD ($)
shares
Jul. 31, 2016
Dec. 31, 2024
USD ($)
item
$ / shares
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Jun. 12, 2024
USD ($)
May 31, 2024
Dec. 31, 2022
shares
Jul. 13, 2018
Dec. 31, 2016
USD ($)
shares
Stockholders' Equity                        
Common stock, shares authorized | shares           200,000,000 200,000,000          
Common stock par value (in dollars per share) | $ / shares           $ 0.0001 $ 0.0001          
Preferred stock, shares authorized | shares           2,000,000 2,000,000          
Preferred Stock, Shares Issued | shares           250,000 250,000          
Common stock subscribed (in shares) | shares           69,046 7,061          
Aggregate value of shares subscribed | $           $ 611,000 $ 591,000          
Proceeds from issuance of common shares | $           6,512,000 4,398,000          
Aggregate fees of stock issuance | $           1,353,000 443,000          
Deemed dividend for issuance of warrants | $       $ 7,800,000                
Research and development - licenses acquired | $           $ 861,000 $ 527,000          
At the Market Offering                        
Stockholders' Equity                        
Agent commission (as a percent)                 3.00%   3.00%  
Issuance of common shares (in shares) | shares           140,000 1,034          
Price per common stock | $ / shares           $ 18.78 $ 158.07          
Proceeds from issuance of common shares | $           $ 2,600,000 $ 163,000          
Aggregate fees of stock issuance | $           100,000 3,000          
Proceeds from issuance of Common Stock, net of offering costs | $           2,500,000 $ 160,000          
Registration Statements | Maximum                        
Stockholders' Equity                        
Shelf Registration statement, value of securities authorized to be sold | $     $ 200,000,000                  
2021 S-3                        
Stockholders' Equity                        
Issuance of common shares (in shares) | shares     4,400,000                  
2024 S-3                        
Stockholders' Equity                        
Sale of Stock aggregate offering price | $               $ 40,000,000        
Shares available for future issuance | $           $ 34,800,000            
June 2024 Registered Direct Offering                        
Stockholders' Equity                        
Issuance of common shares (in shares) | shares 60,500                      
Price per common stock | $ / shares $ 20.5                      
Common Shares                        
Stockholders' Equity                        
Number of votes per share | item           1            
Class A common shares                        
Stockholders' Equity                        
Common stock, shares authorized | shares                   1,000,000    
Director appointment right, period           10 years            
Class A Preferred Shares                        
Stockholders' Equity                        
Preferred Stock, Shares Issued | shares           250,000            
Series A-3 warrant                        
Stockholders' Equity                        
Number of shares issuable upon exercise of warrants shares | shares       337,552                
Exercise of warrants (in shares) | shares       82,000                
Class of warrant or right, shares held in abeyance | shares       255,552   185,880            
Fortress Biotech, Inc                        
Stockholders' Equity                        
Aggregate value of shares subscribed | $                       $ 900
Shares issued for services (in shares) | shares   7,061       23,450 1,319          
Proceeds from issuance of common shares | $             $ 200,000          
Percentage of fully diluted equity           2.50% 2.50%          
Fortress Biotech, Inc | At the Market Offering                        
Stockholders' Equity                        
Common stock subscribed (in shares) | shares             25          
Shares issued for services (in shares) | shares           3,509            
Price per common stock | $ / shares           $ 18.78            
Proceeds from issuance of common shares | $           $ 2,600,000 $ 4,400,000          
Fortress Biotech, Inc | May 2024 Equity Offering                        
Stockholders' Equity                        
Proceeds from issuance of common shares | $           4,000,000            
Fortress Biotech, Inc | June 2024 Registered Direct Offering                        
Stockholders' Equity                        
Proceeds from issuance of common shares | $           2,500,000            
Fortress Biotech, Inc | October registered direct offering                        
Stockholders' Equity                        
Proceeds from issuance of common shares | $           $ 4,000,000            
Fortress Biotech, Inc | Common Shares                        
Stockholders' Equity                        
Common stock subscribed (in shares) | shares                       2,666
Fortress Biotech, Inc | Class B Common Shares                        
Stockholders' Equity                        
Common stock subscribed (in shares) | shares                       7,000,000
Fortress Biotech, Inc | Class A Preferred Shares                        
Stockholders' Equity                        
Percentage of fully diluted equity         2.50%